New Delhi, July 14 -- Sun Pharma on Monday announced it has settled a patent row with American biopharma company Incyte Corporation over its hair-loss drug, paving the way for its launch in the US. The Mumbai-based drugmaker, embroiled in the lawsuit since last year, launched the specialty drug in the world's largest pharmaceutical market on Monday.

Leqselvi (oral deuruxolitinib) is indicated for treatment of adults with severe alopecia areata.

Under the terms of settlement and licensing agreement, the two companies will seek a dismissal of the pending litigation in the United States District Court for the District of New Jersey, the company said in a release.

Sun and Incyte will mutually release each other of all claims that were rais...